Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 24, Issue 1, 2018, Pages 19-26

  MacDonald, Kelli P A ^a   Betts, Brian C ^b   Couriel, Daniel ^c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Chronic GVHD; Graft versus host disease; Interleukin 17A; JAK inhibitor

Indexed keywords

ANTIFIBROTIC AGENT; CSF 1; CYTOKINE; INTERLEUKIN 17; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; B LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC INFLAMMATION; DISEASE CONTROL; DRUG SELECTIVITY; EFFECTOR CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH17 CELL; TISSUE INJURY; ALLOTRANSPLANTATION; CHRONIC DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; THERAPY; TRENDS;

CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-17; JANUS KINASE INHIBITORS; THERAPEUTICS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85038961905     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.10.006     Document Type: Review

References (123)

1. Filipovich, A.H., Weisdorf, D., Pavletic, S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005), 945–956.
2. Jagasia, M.H., Greinix, H.T., Arora, M., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21 (2015), 389–401.
3. Flowers, M.E., Storer, B., Carpenter, P., et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 14 (2008), 1380–1384.
4. Wolff, D., Schleuning, M., von Harsdorf, S., et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 17 (2011), 1–17.
5. Murata, M., Fujimoto, M., Matsushita, T., et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci 50 (2008), 240–242.
6. Yoshizaki, A., Yanaba, K., Iwata, Y., et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 185 (2010), 2502–2515.
7. Wasilewska, A., Winiarska, M., Olszewska, M., Rudnicka, L., Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol 33 (2016), 247–252.
8. Alexander, K.A., Flynn, R., Lineburg, K.E., et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 124 (2014), 4266–4280.
9. Hill, G.R., Olver, S.D., Kuns, R.D., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116 (2010), 819–828.
10. Forcade, E., Paz, K., Flynn, R., et al. An activated Th17-prone T-cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2, 2017.
11. Kennedy, G.A., Varelias, A., Vuckovic, S., et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15 (2014), 1451–1459.
12. Tawara, I., Koyama, M., Liu, C., et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 17 (2011), 77–88.
13. Gartlan, K.H., Markey, K.A., Varelias, A., et al. Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood 126 (2015), 1609–1620.
14. Gartlan, K.H., Varelias, A., Koyama, M., et al. Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. Blood Advances 1 (2017), 341–351.
15. Banerjee, D., Zhao, L., Wu, L., et al. Small molecule mediated inhibition of RORgamma-dependent gene expression and autoimmune disease pathology in vivo. Immunology 147 (2016), 399–413.
16. Withers, D.R., Hepworth, M.R., Wang, X., et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing T(H)17 cells and preserving ILC3. Nat Med 22 (2016), 319–323.
17. Li, W., Liu, L., Gomez, A., et al. Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight, 1, 2016.
18. Hume, D.A., MacDonald, K.P., Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119 (2012), 1810–1820.
19. Duffield, J.S., Forbes, S.J., Constandinou, C.M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115 (2005), 56–65.
20. Gangadharan, B., Hoeve, M.A., Allen, J.E., et al. Murine gamma herpesvirus-induced fibrosis is associated with the development of alternatively activated macrophages. J Leuk Biol 84 (2008), 50–58.
21. MacDonald, K.P., Palmer, J.S., Cronau, S., et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116 (2010), 3955–3963.
22. Bruggen, M.C., Klein, I., Greinix, H., et al. Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood 123 (2014), 290–299.
23. Bonner, J.C., Osornio-Vargas, A.R., Badgett, A., Brody, A.R., Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor-AA, -AB, and -BB isoforms secreted by rat alveolar macrophages. Am J Respir Cell Mol Biol 5 (1991), 539–547.
24. Wahl, S.M., McCartney-Francis, N., Allen, J.B., Dougherty, E.B., Dougherty, S.F., Macrophage production of TGF-beta and regulation by TGF-beta. Ann N Y Acad Sci 593 (1990), 188–196.
25. Arai, M., Ikawa, Y., Chujo, S., et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci 69 (2013), 250–258.
26. Barron, L., Wynn, T.A., Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol 300 (2011), G723–G728.
27. Banovic, T., MacDonald, K.P., Morris, E.S., et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood 106 (2005), 2206–2214.
28. Shahrara, S., Pickens, S.R., Dorfleutner, A., Pope, R.M., IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 182 (2009), 3884–3891.
29. Ge, S., Hertel, B., Susnik, N., et al. Interleukin 17 receptor A modulates monocyte subsets and macrophage generation in vivo. PLoS One, 9, 2014 e85461.
30. Erbel, C., Akhavanpoor, M., Okuyucu, D., et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 193 (2014), 4344–4355.
31. Du, J., Paz, K., Flynn, R., et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood 129 (2017), 2570–2580.
32. Onishi, R.M., Gaffen, S.L., Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129 (2010), 311–321.
33. Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol Rev 228 (2009), 273–287.
34. Carniti, C., Gimondi, S., Vendramin, A., et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res 21 (2015), 3740–3749.
35. Choi, J., Ziga, E.D., Ritchey, J., et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 120 (2012), 4093–4103.
36. Spoerl, S., Mathew, N.R., Bscheider, M., et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123 (2014), 3832–3842.
37. Zeiser, R., Burchert, A., Lengerke, C., et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29 (2015), 2062–2068.
38. Betts, B.C., Abdel-Wahab, O., Curran, S.A., et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 118 (2011), 5330–5339.
39. Heine, A., Held, S.A., Daecke, S.N., et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122 (2013), 1192–1202.
40. Macchi, P., Villa, A., Giliani, S., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995), 65–68.
41. Kreins, A.Y., Ciancanelli, M.J., Okada, S., et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 212 (2015), 1641–1662.
42. Schroeder, M.A., Khoury, H.J., Jagasia, M., et al. A phase I trial of Janus kinase (JAK) inhibition with INCB039110 in acute graft-versus-host disease (aGVHD) [abstract]. Blood, 128, 2016, 390.
43. Taylor, P., Westhovens, R., et al., Aa AVd. THU0206 The jak1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients [abstract]. Ann Rheum Dis 76:suppl 2 (2017), 281–282.
44. Betts, B.C., Bastian, D., Nguyen, H., et al. Targeting JAK2 by gene knockout or pacritinib treatment reduces Gvhd and xenograft rejection by promoting induced treg differentiation [abstract]. Blood, 126, 2015, 1874.
45. Choi, J., Cooper, M.L., Vij, K.R., et al. Pharmacologic co-blockade of IFNγR and IL6R pathways to prevent and treat GvHD [abstract]. Blood, 128, 2016, 3353.
46. Parampalli Yajnanarayana, S., Stubig, T., Cornez, I., et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol 169 (2015), 824–833.
47. Schonberg, K., Rudolph, J., Vonnahme, M., et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75 (2015), 2187–2199.
48. Curran, S.A., Shyer, J.A., St Angelo, E.T., et al. Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1/2 blockade. Cancer Immunol Res 5 (2017), 52–60.
49. Heine, A., Brossart, P., Wolf, D., Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood 122 (2013), 3843–3844.
50. Ghoreschi, K., Jesson, M.I., Li, X., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186 (2011), 4234–4243.
51. Rizzi, M., Lorenzetti, R., Fischer, K., et al. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun 77 (2017), 55–66.
52. Lee, E.B., Fleischmann, R., Hall, S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
53. Westhovens, R., Taylor, P.C., Alten, R., et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76 (2017), 998–1008.
54. Saouaf, S.J., Mahajan, S., Rowley, R.B., et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci USA 91 (1994), 9524–9528.
55. Mascarenhas, J.O., Talpaz, M., Gupta, V., et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 102 (2017), 327–335.
56. Bissonnette, R., Luchi, M., Fidelus-Gort, R., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral Janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat 27 (2016), 332–338.
57. Beatty, G.L., Shahda, S., Beck, J.T., et al. A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC). J Clin Oncol, 35(4 suppl), 2017, 362.
58. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (2012), 787–798.
59. Betts, B.C., Veerapathran, A., Pidala, J., et al. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining treg and antitumor CTL function. Sci Transl Med, 9, 2017.
60. Mesa, R.A., Vannucchi, A.M., Mead, A., et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol 4 (2017), e225–e236.
61. Harrison, C.N., Schaap, N., Vannucchi, A.M., et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4 (2017), e317–e324.
62. Sandborn, W.J., Su, C., Sands, B.E., et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376 (2017), 1723–1736.
63. Ibrahim, O., Bayart, C.B., Hogan, S., Piliang, M., Bergfeld, W.F., Treatment of alopecia areata with tofacitinib. JAMA Dermatol 153 (2017), 600–602.
64. Kennedy Crispin, M., Ko, J.M., Craiglow, B.G., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1, 2016, e89776.
65. Winthrop, K.L., The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13 (2017), 234–243.
66. Chen, X., Das, R., Komorowski, R., et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114 (2009), 891–900.
67. Khandelwal, P., Teusink-Cross, A., Davies, S.M., et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 23 (2017), 1122–1127.
68. Betts, B.C., Sagatys, E.M., Veerapathran, A., et al. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. J Leukoc Biol 97 (2015), 807–819.
69. Sarantopoulos, S., Ritz, J., Aberrant B-cell homeostasis in chronic GVHD. Blood 125 (2015), 1703–1707.
70. Zeiser, R., Negrin, R.S., Introduction to a review series on chronic GVHD: from pathogenic B-cell receptor signaling to novel therapeutic targets. Blood 129 (2017), 1–2.
71. Shimabukuro-Vornhagen, A., Hallek, M.J., Storb, R.F., von Bergwelt-Baildon, M.S., The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114 (2009), 4919–4927.
72. Rozovski, U., Wu, J.Y., Harris, D.M., et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123 (2014), 3797–3802.
73. Ding, C., Chen, X., Dascani, P., et al. STAT3 signaling in B cells is critical for germinal center maintenance and contributes to the pathogenesis of murine models of lupus. J Immunol 196 (2016), 4477–4486.
74. MacDonald, K.P., Blazar, B.R., Hill, G.R., Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127 (2017), 2452–2463.
75. Hedrich, C.M., Rauen, T., Apostolidis, S.A., et al. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci USA 111 (2014), 13457–13462.
76. Srinivasan, M., Flynn, R., Price, A., et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119 (2012), 1570–1580.
77. O'Shea, J.J., Kontzias, A., Yamaoka, K., Tanaka, Y., Laurence, A., Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72:suppl 2 (2013), ii111–ii115.
78. Dougados, M., van der Heijde, D., Chen, Y.C., et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76 (2017), 88–95.
79. Okiyama, N., Furumoto, Y., Villarroel, V.A., et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol 134 (2014), 992–1000.
80. Lee, S.J., Wolff, D., Kitko, C., et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 21 (2015), 984–999.
81. Cooke, K.R., Luznik, L., Sarantopoulos, S., et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant 23 (2017), 211–234.
82. Koehn, B.H., Zeiser, R., Blazar, B.R., Inflammasome effects in GvHD. Oncotarget 6 (2015), 38444–38445.
83. Church, L.D., McDermott, M.F., Canakinumab: a human anti-IL-1beta monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 6 (2010), 831–841.
84. Yao, Y., Richman, L., Higgs, B.W., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60 (2009), 1785–1796.
85. Soiffer, R.J., Weller, E., Alyea, E.P., et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 19 (2001), 1152–1159.
86. Ho, V.T., Soiffer, R.J., The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001), 3192–3204.
87. Kroger, N., Solano, C., Wolschke, C., et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374 (2016), 43–53.
88. Socie, G., Schmoor, C., Bethge, W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 117 (2011), 6375–6382.
89. Robinson, T.M., O'Donnell, P.V., Fuchs, E.J., Luznik, L., Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53 (2016), 90–97.
90. Blanco, B., Perez-Simon, J.A., Sanchez-Abarca, L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107 (2006), 3575–3583.
91. Kim, J.S., Lee, J.I., Shin, J.Y., et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation 88 (2009), 1349–1359.
92. Sun, K., Welniak, L.A., Panoskaltsis-Mortari, A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101 (2004), 8120–8125.
93. Herrera, A.F., Kim, H.T., Bindra, B., et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 20 (2014), 1737–1743.
94. Pai, C.C., Chen, M., Mirsoian, A., et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood 124 (2014), 1677–1688.
95. Koura, D.T., Horan, J.T., Langston, A.A., et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant 19 (2013), 1638–1649.
96. Huu, D.L., Matsushita, T., Jin, G., et al. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum 65 (2013), 1624–1635.
97. Chi, H., Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 32 (2011), 16–24.
98. D'Ambrosio, D., Freedman, M.S., Prinz, J., Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 7 (2016), 18–33.
99. Fehervari, Z., Sakaguchi, S., Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol 16 (2004), 203–208.
100. Maloy, K.J., Salaun, L., Cahill, R., Dougan, G., Saunders, N.J., Powrie, F., CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197 (2003), 111–119.
101. Koreth, J., Kim, H.T., Jones, K.T., et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood 128 (2016), 130–137.
102. Brunstein, C.G., Miller, J.S., McKenna, D.H., et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127 (2016), 1044–1051.
103. Di Ianni, M., Falzetti, F., Carotti, A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117 (2011), 3921–3928.
104. Brunstein, C.G., Miller, J.S., Cao, Q., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117 (2011), 1061–1070.
105. Couriel, D.R., Hosing, C., Saliba, R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107 (2006), 3074–3080.
106. Biagi, E., Di Biaso, I., Leoni, V., et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84 (2007), 31–39.
107. Bruserud, O., Tvedt, T.H., Paulsen, P.Q., et al. Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies. Cancer Immunol Immunother 63 (2014), 757–777.
108. Di Biaso, I., Di Maio, L., Bugarin, C., et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 87 (2009), 1422–1425.
109. Matsuoka, K., Koreth, J., Kim, H.T., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med, 5, 2013, 179ra143.
110. Koreth, J., Matsuoka, K., Kim, H.T., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365 (2011), 2055–2066.
111. Cutler, C., Miklos, D., Kim, H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006), 756–762.
112. Ratanatharathorn, V., Ayash, L., Reynolds, C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003), 505–511.
113. Ratanatharathorn, V., Carson, E., Reynolds, C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133 (2000), 275–279.
114. Flynn, R., Allen, J.L., Luznik, L., et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 125 (2015), 4085–4094.
115. Tan, S.L., Liao, C., Lucas, M.C., Stevenson, C., DeMartino, J.A., Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives. Pharmacol Ther 138 (2013), 294–309.
116. Dubovsky, J.A., Flynn, R., Du, J., et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124 (2014), 4867–4876.
117. Schutt, S.D., Fu, J., Nguyen, H., et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PLoS One, 10, 2015 e0137641.
118. Miklos, D., Cutler, C., Arora, M., et al. Multicenter, open-label Phase 1b/2 study of Ibrutinib in steroid dependent/refractory chronic graft-versus-host disease (cGVHD) [abstract]. Bone Marrow Transplant 51:suppl S1 (2016), S176–S177.
119. Miklos, D., Arora, M., et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Blood, 128, 2016 LBA-3.
120. Distler, A., Lang, V., Del Vecchio, T., et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 73 (2014), 1264–1268.
121. Horn, A., Palumbo, K., Cordazzo, C., et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 64 (2012), 2724–2733.
122. Ruiz-Heiland, G., Horn, A., Zerr, P., et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 71 (2012), 400–407.
123. Zerr, P., Palumbo-Zerr, K., Distler, A., et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 120 (2012), 2909–2917.